Introduction {#sec1}
============

Organophosphorus compounds are an important class of organic compounds, exclusively applicable in organic synthesis,^[@ref1]^ material sciences,^[@ref2]^ medicinal chemistry,^[@ref3]^ agro industry,^[@ref4]^ and coordination chemistry.^[@ref5]^ The chemical and physical properties of parent molecules are changed by the incorporation of the phosphate group. Many P-containing heterocycles show excellent biological activities.^[@ref6]^ Moreover, phosphonate esters are frequently used as prodrugs in the pharmaceutical industry.^[@ref7]^ Therefore, development of newer methodologies for introducing the phosphonate esters into organic molecules is highly demanding in organic synthesis. First, in 1980 Hirao and coworkers described palladium-catalyzed phosphorylation of aryl iodides or bromides.^[@ref8]^ After that, many cross-coupling reactions between aryl (pseudo)halides, aryltriflates, tosylates, boronic acids, aryl diazonium salts, alkenyl/alkynyl carboxyl acids, or nucleophilic heteroarenes and *H*-phosphonates or *H*-phosphine oxides have been developed using transition-metal catalysts.^[@ref9]^ However, recently direct oxidative C--H phosphorylation using transition-metal-catalyst has drawn much attention to the organic synthetic chemist.

Indazole, a N-containing heterocyclic compound, acts as efficient bioisosteres of indole and benzimidazole in pharmaceutical chemistry.^[@ref10]^ It has gained considerable attention in pharmaceuticals due to their broad range of biological activities^[@ref11]^ like antitumor,^[@cit11a]^ antimicrobial,^[@cit11b]^ antiinflammatory,^[@cit11c]^ antidepressant,^[@cit11d]^ anti platelet,^[@cit11e]^ anticancer,^[@cit11f]^ and HIV-protease inhibition.^[@cit11g]^ Indazoles are used as estrogen receptors, bacterial gyrase β-inhibitors^[@cit11h]^ and also have potential activity towards the imidazoline I~2~-receptor and 5-HT1A receptors. It is the core structure of many drug molecules^[@ref12]^ such as MK-4827 (anticancer agent), pazopanib, bendazac (votrient, tyrosine kinase inhibitor), and gamendazole ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Owing to their high biological activities, various methodologies have been made for the synthesis^[@ref13]^ and functionalization^[@ref14]^ of indazoles. Our group was also actively involved for functionalization of 2*H*-indazoles.^[@ref15]^ Very recently, our group reported phosphorylation of 2*H*-indazole with diphenylphosphine oxide via visible light photoredox catalysis.^[@cit15b]^ But in our previous conditions^[@cit15b]^ phosphonate ester did not react with 2*H*-indazole. It is worthy to mention that Mn(III) acetate is found to be an effective catalyst for various C--H functionalization.^[@ref16],[@ref17]^ Considering the high importance of both phosphonate esters and indazole moiety, herein we describe a direct C--H phosphorylation of 2*H*-indazole with dialkyl phosphites using manganese(III) acetate at 80 °C ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Some biologically active 2*H*-indazole-containing molecules.](ao-2019-01121p_0001){#fig1}

![Phosphorylation of Indazoles](ao-2019-01121p_0002){#sch1}

Results and Discussion {#sec2}
======================

To optimize the phosphorylation of 2*H*-indazole, we commenced our study by taking 2*H*-indazole (**1a**) and diethyl phosphite (**2a**) as model substrates. At first, the reaction was carried out using 2 equiv Mn(OAc)~3~·2H~2~O in CH~3~CN at 80 °C. Interestingly, diethyl (2-phenyl-2*H*-indazol-3-yl)phosphonate (**3aa**) was formed in 52% yield after 10 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). The yield of the reaction did not improve even after 12 h. Encouraged by this initial result, the reaction was carried out under different conditions to optimize the reaction and the results are summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. Initially, we checked the solvent effect taking other different solvents like AcOH, EtOH, NMP, 1,2-DCE, and DMF ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2--6). Better results were obtained in AcOH providing the desired phosphorylated product in 88% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 2). The yield was dropped to 41% with diminishing the amount of Mn(III) acetate (1 equiv) but no improvement of yield was observed with the increase in load of Mn(III) acetate (3 equiv) as well as diethyl phosphite (3 equiv) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 7 and 8). The reaction yield did not increase significantly at 100 °C but the yield was diminished to 58% with lowering the reaction temperature (60 °C) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} entries 9 and 10). Mn(II) acetate is not suitable for such transformation ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 11). Moreover the reaction did not proceed in the absence of Mn(III) acetate ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 12). Other catalysts like Cu(acac)~2,~ MnO~2,~ CuI, and Fe(acac)~3~ were unable to produce the desired product ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 13--16). Finally, we got the optimized reaction conditions using 2 equiv Mn(OAc)~3~·2H~2~O and 2 equiv diethyl phosphite in AcOH at 80 °C for 10 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 2).

###### Optimization of the Reaction Conditions for Phosphorylation of Indazoles[a](#t1fn1){ref-type="table-fn"}

![](ao-2019-01121p_0008){#GRAPHIC-d7e341-autogenerated}

   entry   catalyst (2 equiv)   solvent (2 mL)   yield (%)[b](#t1fn2){ref-type="table-fn"}
  ------- -------------------- ---------------- -------------------------------------------
     1     Mn(OAc)~3~·2H~2~O       CH~3~CN                          52
     2     Mn(OAc)~3~·2H~2~O         AcOH                           88
     3     Mn(OAc)~3~·2H~2~O         EtOH                          trace
     4     Mn(OAc)~3~·2H~2~O         NMP                            32
     5     Mn(OAc)~3~·2H~2~O       1,2-DCE                          35
     6     Mn(OAc)~3~·2H~2~O         DMF                            21
     7     Mn(OAc)~3~·2H~2~O         AcOH           41[c](#t1fn3){ref-type="table-fn"}
     8     Mn(OAc)~3~·2H~2~O         AcOH           82[d](#t1fn4){ref-type="table-fn"}
     9     Mn(OAc)~3~·2H~2~O         AcOH           81[e](#t1fn5){ref-type="table-fn"}
    10     Mn(OAc)~3~·2H~2~O         AcOH           58[f](#t1fn6){ref-type="table-fn"}
    11         Mn(OAc)~2~            AcOH                           NR
    12             \_                AcOH                           NR
    13        Cu(acac)~2~            AcOH                           NR
    14           MnO~2~              AcOH                           NR
    15            CuI                AcOH                           NR
    16        Fe(acac)~3~            AcOH                           NR

Reaction conditions: **1a** (0.2 mmol), catalyst (2 equiv), diethyl phosphite (2 equiv), and solvent (2 mL) for 10 h at 80 °C.

Isolated yield.

The reaction was performed using 1 equiv and,

The reaction was performed using 3 equiv Mn(III) acetate at 80 °C.

The reaction was conducted at 100 °C and.

The reaction was conducted at 60 °C. NR = no reaction.

After optimizing the reaction conditions, we explored the substrate scope to study the generality of this protocol ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). A series of phosphorylated 2*H*-indaozoles were synthesized in moderate to good yields under the present reaction conditions. First, we examined the effect of the different N-2 substituents on 2*H*-indazoles. Electron-donating groups like −Me and −OMe substituted 2*H*-indazoles reacted very smoothly under optimized reaction conditions (**3ba**--**3ea**). Halogen substituted 2-phenyl-2*H*-indazoles also produced the phosphorylated product in good yields (**3fa**--**3ja**). In addition, 2-(naphthalen-1-yl)-2*H*-indazole also worked well (**3ka**). However, ortho-substituted 2-phenyl-2*H*-indazoles, *N*-alkyl, and *N*-benzyl substituted 2-*H*-indazole were not suitable for this reaction. Moreover, 1*H*-indazole and unprotected 2*H*-indazole remained unreactive towards the phosphorylation reaction. In addition, 1*H*-pyrazolo\[3,4-*d*\]pyrimidin-4-amine and 1*H*-pyrazole did not respond in this reaction. Furthermore, the gram-scale reaction was carried out under the normal laboratory set up using 2-phenyl-2*H*-indazole (**1a**, 5 mmol) and diethyl phosphite (**2a**, 10 mmol) under the standard reaction conditions. Delightfully, the reaction offered the corresponding product (**3aa**) with comparable yield (82%) which clearly elucidates the practical applicability of this present methodology.

![Substrate Scope\
Reaction conditions: **1** (0.2 mmol), Mn(OAc)~3~·2H~2~O (2 equiv), diethyl phosphite (**2a**, 2 equiv), and AcOH (2 mL) for 10 h at 80 °C.\
On a 5 mmol scale.](ao-2019-01121p_0003){#sch2}

Next, we checked the effect of different substituents at the arene part of 2*H*-indazoles ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). Halogen (−F and −Cl) containing substrates efficiently reacted with diethyl phosphite to produce the desired products in good yields (**3la**--**3na**). 5-Methoxy-2-(4-methoxyphenyl)-2*H*-indazole and diethyl 5-methoxy-2-(*p*-tolyl)-2*H*-indazole also reacted effectively under the optimized reaction conditions to form the desired products in good yields (**3oa** and **3pa**).

![Substrate Scope of Indazole\
Reaction conditions: **1** (0.2 mmol), Mn(OAc)~3~·2H~2~O (2 equiv), diethyl phosphite (**2a**, 2 equiv), and AcOH (2 mL) for 10 h at 80 °C.](ao-2019-01121p_0004){#sch3}

With the optimized conditions, the scope of this protocol was also extended with different phosphorylating agents ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). Dimethyl phosphite and diisopropyl phosphite effectively reacted with differently substituted 2*H*-indazoles to provide the phosphorylated products in moderate to good yields (**3ab**, **3bb**, **3bc**, and **3mc**). But diphenyl phosphite, dibenzyl phosphite, diphenylphosphine oxide, and triethyl phosphite were unable to produce the desired products.

![Substrate Scope of Phosphonate Ester\
Reaction conditions: **1** (0.2 mmol), Mn(OAc)~3~·2H~2~O (2 equiv), dialkyl phosphite (**2**, 2 equiv), and AcOH (2 mL) for 10 h at 80 °C.](ao-2019-01121p_0005){#sch4}

Finally, radical trapping experiments were conducted to probe the mechanistic pathway of this reaction. The present phosphorylation reaction is completely suppressed with the addition of radical scavengers like, 2,6-di-*tert*-butyl-4-methyl phenol, 2,2,6,6-tetramethylpiperidine-1-oxyl, and *p*-benzoquinone. These results suggest a radical mechanism of the present reaction [Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}.

![Radical Trapping Experiments](ao-2019-01121p_0006){#sch5}

In accordance with the control experimental results and previous literature reports,^[@ref17]^ we proposed a plausible mechanism of phosphorylation reaction in [Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}. At first, phosphoryl radical (**A**) is formed by Mn(III) acetate. Then, addition of the phosphoryl radical **A** at the C-3 position of 2*H*-indazole (**1a**) provides the intermediate **B**. The elimination of the hydrogen radical from intermediate **B** gives the desired C--H phosphorylated product **3aa**.

![Probable Mechanism](ao-2019-01121p_0007){#sch6}

Conclusions {#sec3}
===========

In summary, we have established a convenient, efficient, and simple method for the C(sp^2^)--H phosphorylation of 2*H*-indazoles using dialkylphosphites as phosphorylating agent in the presence of Mn(OAc)~3~·2H~2~O. This protocol is featured with regioselectivity, high functional group tolerance, simple reaction conditions, and scalability. Based on our experimental result, a radical mechanistic pathway has been suggested. To the best of our knowledge, we are not aware of any earlier report of direct phosphorylation of the 2*H*-indazole moiety with phosphonate esters. We believe this direct C--P bond formation strategy will achieve significant importance in material sciences, pharmaceutical chemistry, and also in organic synthesis.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

All reagents were received from commercial sources, unless specified otherwise. Dried and distilled solvents were used. All reactions involving moisture sensitive reactants were performed using oven dried glassware. ^1^H NMR spectra were recorded on a 400 MHz spectrometer, ^13^C{^1^H} and ^31^P NMR spectra were determined at 100 and 162 MHz, respectively, in CDCl~3~ solution. Chemical shifts as the internal standard were referenced to CDCl~3~ (δ = 7.26 for ^1^H and δ = 77.16 for ^13^C{^1^H} NMR) and expressed in ppm. Coupling constants (*J*) are expressed in hertz (Hz). The following abbreviations were used to explain the multiplicities: s (singlet), d (doublet), dd (doublet of doublet), t (triplet), m (multiplet), and q (quartet). Thin layer chromatography was carried out by using thin-layer chromatography (TLC) plates (silica-gel-coated glass slide) with eluants hexane-ethyl acetate and the reaction was monitored under UV radiation. All the derivatives of 2*H*-indazole were prepared by the reported methods.^[@cit13d],[@cit14c],[@cit15d]^ Compounds **1a**,^[@cit13d]^**1b**,^[@cit13d]^**1c**,^[@cit15d]^**1d**,^[@cit14c]^**1f**,^[@cit15d]^**1g**,^[@cit13d]^**1h**,^[@cit14c]^**1i**,^[@cit15d]^**1j**,^[@cit14c]^**1l**,^[@cit13d]^**1m**,^[@cit13d]^**1o**,^[@cit15d]^ and **1p**([@cit15d]) are known, and the spectroscopic and physical data are completely matched with those from the literature.

2-(3-Methoxyphenyl)-2*H*-indazole (**1e**) {#sec4.2}
------------------------------------------

Yellow liquid (92%, 618.24 mg); *R*~f~ = 0.50 (PE/EA = 93:07); ^1^H NMR (400 MHz, CDCl~3~): δ 8.33 (d, *J* = 0.4 Hz, 1H), 7.82--7.80 (m, 1H), 7.66 (d, *J* = 8.4 Hz, 1H), 7.52 (t, *J* = 2.4 Hz, 1H), 7.41--7.30 (m, 3H), 7.11--7.08 (m, 1H), 6.92--6.89 (m, 1H), 3.85 (s, 3H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 160.5, 149.6, 141.5, 130.2, 126.8, 122.6, 122.4, 120.5, 120.4, 117.8, 113.8, 112.7, 106.7, 55.5; Anal. Calcd for C~14~H~12~N~2~O: C, 74.98; H, 5.39; N, 12.49%. Found: C, 75.16; H, 5.30; N, 12.58%.

2-(Naphthalen-1-yl)-2*H*-indazole (**1k**) {#sec4.3}
------------------------------------------

Brown solid (83%, 607.5 mg); *R*~f~ = 0.45 (PE/EA = 98:02); mp 85--86 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.31 (d, *J* = 0.8 Hz, 1H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.96 (d, *J* = 8.0 Hz, 1H), 7.87--7.84 (m, 1H), 7.80--7.78 (m, 1H), 7.74 (d, *J* = 8.8 Hz, 1H), 7.68--7.66 (m, 1H), 7.61--7.48 (m, 3H), 7.41--7.37 (m, 1H), 7.21--7.17 (m, 1H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 149.7, 134.3, 129.8, 129.2, 127.7, 127.5, 126.9, 126.7, 125.6, 125.1, 124.0, 123.1, 122.5, 122.2, 120.5, 118.1; Anal. Calcd for C~17~H~12~N~2~: C, 83.58; H, 4.95; N, 11.47%. Found: C, 83.71; H, 5.00; N, 11.37%.

5-Chloro-2-phenyl-2*H*-indazole (**1n**) {#sec4.4}
----------------------------------------

Yellow solid (90%, 615.6 mg); *R*~f~ = 0.50 (PE/EA = 97:03); mp 79--80 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.25 (s, 1H), 7.78 (d, *J* = 8.0 Hz, 2H), 7.64 (d, *J* = 9.2 Hz, 1H), 7.58 (s, 1H), 7.44 (t, *J* = 8.0 Hz, 2H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.17--7.15 (m, 1H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.2, 140.3, 129.7, 129.4, 128.3, 128.2, 123.2, 121.0, 120.1, 119.6, 119.1; Anal. Calcd for C~13~H~9~ClN~2~: C, 68.28; H, 3.97; N, 12.25%. Found: C, 68.09; H, 3.94; N, 12.30%.

Typical Experimental Procedure for the Compound Diethyl(2-phenyl-2*H*-indazol-3-yl)phosphonate (**3aa**) {#sec4.5}
--------------------------------------------------------------------------------------------------------

A mixture of 2-phenyl-2*H*-indazole (**1a**) (0.2 mmol 38.8 mg), diethylphosphite (**2a**, 2 equiv, 55.2 mg), and Mn(OAc)~3~·2H~2~O (2 equiv, 107.2 mg) was taken in a reaction tube. Then, AcOH was added to the reaction mixture and stirred at 80 °C for 10 h. After completion of the reaction (TLC), the reaction mixture was quenched with sodium bicarbonate solution (5 mL). The reaction mixture was then extracted with ethyl acetate. The organic phase was dried over anhydrous Na~2~SO~4~ and concentrated under reduced pressure to get the crude residue which was purified by column chromatography on silica gel (60--120 mesh) using petroleum ether/ethylacetate = 80:20 as an eluant to afford the pure product diethyl (2-phenyl-2*H*-indazol-3-yl)phosphonate (**3aa**) (55.44 mg, 84%) as a colorless liquid.

Diethyl(2-phenyl-2*H*-indazol-3-yl)phosphonate (**3aa**) {#sec4.6}
--------------------------------------------------------

Colorless liquid (84%, 55.44 mg); *R*~f~ = 0.5 (PE/EA = 80:20); ^1^H NMR (400 MHz, CDCl~3~): δ 8.11 (d, *J* = 8.8 Hz, 1H), 7.86--7.83 (m, 1H), 7.68--7.66 (m, 2H), 7.53--7.50 (m, 3H), 7.41--7.37 (m, 1H), 7.30--7.27 (m, 1H), 4.13--3.93 (m, 4H), 1.18 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.7 (d, *J* = 17.0 Hz), 141.0, 129.2 (d, *J* = 82.0 Hz), 128.4 (d, *J* = 19.0 Hz), 127.0, 126.4, 124.8 (d, *J* = 13.0 Hz), 122.7, 121.4, 119.9, 118.3, 62.9 (d, *J* = 6.0 Hz), 16.1 (d, *J* = 8.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.72; Anal. Calcd for C~17~H~19~N~2~O~3~P: C, 61.81; H, 5.80; N, 8.48%. Found: C, 61.60; H, 5.84; N, 8.59%.

Diethyl(2-(*p*-tolyl)-2*H*-indazol-3-yl)phosphonate (**3ba**) {#sec4.7}
-------------------------------------------------------------

White solid (86%, 59.16 mg); *R*~f~ = 0.55 (PE/EA = 70:30); mp 88--89 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.45--8.43 (m, 1H), 8.19--8.16 (m, 1H), 7.89--7.87 (m, 2H), 7.72--7.70 (m, 1H), 7.64 (d, *J* = 8.8 Hz, 2H), 7.61--7.59 (m, 1H), 4.46--4.29 (m, 4H), 2.78 (s, 3H), 1.54 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.7 (d, *J* = 16.0 Hz), 139.7, 138.5, 129.4 (d, *J* = 13.0 Hz), 128.4 (d, *J* = 18.0 Hz), 126.9, 126.1, 124.7 (d, *J* = 15.0 Hz), 122.5 (d, *J* = 21.0 Hz), 118.3, 115.5, 62.8 (d, *J* = 5.0 Hz), 21.3, 16.1 (d, *J* = 7.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.89; Anal. Calcd for C~18~H~21~N~2~O~3~P: C, 62.78; H, 6.15; N, 8.14%. Found: C, 62.97; H, 6.18; N, 8.05%

Diethyl(2-(*m*-tolyl)-2*H*-indazol-3-yl)phosphonate (**3ca**) {#sec4.8}
-------------------------------------------------------------

Yellow liquid (88%, 60.54 mg); *R*~f~ = 0.45 (PE/EA = 75:25); ^1^H NMR (400 MHz, CDCl~3~): δ 8.12--8.10 (m, 1H), 7.85--7.82 (m, 1H), 7.47 (d, *J* = 7.2 Hz, 2H), 7.41--7.36 (m, 2H), 7.32--7.27 (m, 2H), 4.14--3.94 (m, 4H), 2.44 (s, 3H), 1.19 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H}NMR (100 MHz, CDCl~3~): δ 148.6 (d, *J* = 17.0 Hz), 140.9, 138.9, 130.3, 128.5 (d, *J* = 6.0 Hz), 128.3, 126.9 (d, *J* = 2.0 Hz), 124.7, 124.6, 123.4, 122.6, 121.4, 118.3, 62.8 (d, *J* = 5.0 Hz), 21.3, 16.1 (d, *J* = 6.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.82; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~18~H~21~N~2~O~3~PNa, 367.1182; found, 367.1183.

Diethyl(2-(4-methoxyphenyl)-2*H*-indazol-3-yl)phosphonate (**3da**) {#sec4.9}
-------------------------------------------------------------------

Brown gummy mass (86%, 61.92 mg); *R*~f~ = 0.45 (PE/EA = 70:30); ^1^H NMR (400 MHz, CDCl~3~): δ 8.09 (d, *J* = 8.4 Hz, 1H), 7.84--7.81 (m, 1H), 7.60--7.56 (m, 2H), 7.39--7.35 (m, 1H), 7.28--7.25 (m, 1H), 7.02--6.98 (m, 2H), 4.14--3.94 (m, 4H), 3.87 (s, 3H), 1.21 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 160.4, 148.6 (d, *J* = 16.0 Hz), 134.0, 128.3 (d, *J* = 18.0 Hz), 127.6, 126.9, 124.7 (d, *J* = 28.0 Hz), 122.7, 121.3, 118.2, 113.8, 77.3, 62.8 (d, *J* = 5.0 Hz), 55.7, 16.2 (d, *J* = 7.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.96; Anal. Calcd for C~18~H~21~N~2~O~4~P: C, 60.00; H, 5.87; N, 7.77%. Found: C, 60.15; H, 5.82; N, 7.87%.

Diethyl(2-(3-methoxyphenyl)-2*H*-indazol-3-yl)phosphonate (**3ea**) {#sec4.10}
-------------------------------------------------------------------

Yellow liquid (84%, 60.48 mg); *R*~f~ = 0.45 (PE/EA = 70:30); ^1^H NMR (400 MHz, CDCl~3~): δ 8.12 (d, *J* = 8.4 Hz, 1H), 7.86--7.83 (m, 1H), 7.42--7.36 (m, 2H), 7.29--7.26 (m, 3H), 7.06--7.04 (m, 1H), 4.13--3.97 (m, 4H), 3.86 (s, 3H), 1.20 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 159.7, 148.6 (d, *J* = 16.0 Hz), 141.9, 129.4, 128.4 (d, *J* = 18.0 Hz), 127.0, 124.7 (d, *J* = 12.0 Hz), 122.6, 121.4, 118.5, 118.3, 115.8, 111.8, 62.8 (d, *J* = 6.0 Hz), 55.6, 16.1 (d, *J* = 7.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.82; HRMS (ESI-TOF) *m*/*z*: \[M + H\]^+^ calcd for C~18~H~22~N~2~O~4~P, 361.1312; found, 361.1311.

Diethyl(2-(4-fluorophenyl)-2*H*-indazol-3-yl)phosphonate (**3fa**) {#sec4.11}
------------------------------------------------------------------

Brown liquid (74%, 51.50 mg); *R*~f~ = 0.50 (PE/EA = 75:25); ^1^H NMR (400 MHz, CDCl~3~): δ 8.08--8.06 (m, 1H), 7.84--7.81 (m, 1H), 7.67--7.63 (m, 2H), 7.42--7.38 (m, 1H), 7.30--7.27 (m, 1H), 7.23--7.17 (m, 2H), 4.14--3.95 (m, 4H), 1.22 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 164.3, 161.7 (d, *J* = 33.0 Hz), 148.8 (d, *J* = 17.0 Hz), 137.1, 132.7, 128.3 (d, *J* = 9.0 Hz), 126.2 (d, *J* = 211.0 Hz), 125.1, 124.7 (d, *J* = 48.0 Hz), 121.6 (d, *J* = 8.0 Hz), 119.8 (d, *J* = 302.0 Hz), 115.7 (d, *J* = 23.0 Hz), 77.3, 63.0 (d, *J* = 5.0 Hz), 16.2 (d, *J* = 7.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.65; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~17~H~18~FN~2~O~3~PNa, 371.0931; found, 371.0925.

Diethyl(2-(4-chlorophenyl)-2*H*-indazol-3-yl)phosphonate (**3ga**) {#sec4.12}
------------------------------------------------------------------

Yellow liquid (85%, 61.88 mg); *R*~f~ = 0.55 (PE/EA = 70:30); ^1^H NMR (400 MHz, CDCl~3~): δ 8.10--8.07 (m, 1H), 7.85--7.82 (m, 1H), 7.66--7.62 (m, 2H), 7.51--7.48 (m, 2H), 7.42--7.38 (m, 1H), 7.31--7.27 (m, 1H), 4.16--3.97 (m, 4H), 1.23 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.9 (d, *J* = 16.0 Hz), 139.5, 135.6, 129.0, 128.4 (d, *J* = 19.0 Hz), 127.7, 127.3, 125.0, 122.9, 121.3, 118.3, 63.0 (d, *J* = 5.0 Hz), 16.2 (d, *J* = 7.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.57; Anal. Calcd for C~17~H~18~ClN~2~O~3~P: C, 55.98; H, 4.97; N, 7.68%. Found: C, 55.80; H, 5.01; N, 7.63%.

Diethyl(2-(3-chlorophenyl)-2*H*-indazol-3-yl)phosphonate (**3ha**) {#sec4.13}
------------------------------------------------------------------

Brown liquid (81%, 58.96 mg); *R*~f~ = 0.45 (PE/EA = 80:20); ^1^H NMR (400 MHz, CDCl~3~): δ 8.11 (d, *J* = 8.4 Hz, 1H), 7.85--7.82 (m, 1H), 7.73 (t, *J* = 2.0 Hz, 1H), 7.62--7.59 (m, 1H), 7.51--7.38 (m, 3H), 7.31--7.27 (m, 1H), 4.16--4.00 (m, 4H), 1.23 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.9 (d, *J* = 16.0 Hz), 141.9, 134.4, 130.0, 129.7 (d, *J* = 7.0 Hz), 128.5 (d, *J* = 18.0 Hz), 127.4, 126.8, 125.0, 124.7, 122.9, 121.4, 118.3, 63.0 (d, *J* = 5.0 Hz), 16.2 (d, *J* = 7.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.38; Anal. Calcd for C~17~H~18~ClN~2~O~3~P: C, 55.98; H, 4.97; N, 7.68%. Found: C, 56.19; H, 5.02; N, 7.76%.

Diethyl(2-(4-chloro-3-fluorophenyl)-2*H*-indazol-3-yl)phosphonate (**3ia**) {#sec4.14}
---------------------------------------------------------------------------

Brown gummy mass (82%, 62.64 mg); *R*~f~ = 0.45 (PE/EA = 85:15); ^1^H NMR (400 MHz, CDCl~3~): δ 8.09--8.07 (m, 1H), 7.84--7.78 (m, 2H), 7.62--7.58 (m, 1H), 7.43--7.38 (m, 1H), 7.31--7.27 (m, 2H), 4.19--4.00 (m, 4H), 1.25 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 158.6 (d, *J* = 51.0 Hz), 148.9 (d, *J* = 16.0 Hz), 137.4 (d, *J* = 3.0 Hz), 129.0, 128.5, 128.3, 127.5, 126.4 (d, *J* = 8.0 Hz), 125.1, 121.3, 118.3, 116.7, 116.5, 77.3, 63.1 (d, *J* = 6.0 Hz), 16.2 (d, *J* = 7.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.40; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~17~H~17~ClFN~2~O~3~PNa, 405.0542; found, 405.0541.

Diethyl(2-(4-bromophenyl)-2*H*-indazol-3-yl)phosphonate (**3ja**) {#sec4.15}
-----------------------------------------------------------------

Light yellow liquid (79%, 64.62 mg); *R*~f~ = 0.45 (PE/EA = 70:30); ^1^H NMR (400 MHz, CDCl~3~): δ 8.09--8.07 (m, 1H), 7.84--7.82 (m, 1H), 7.67--7.64 (m, 2H), 7.60--7.56 (m, 2H), 7.42--7.38 (m, 1H), 7.31--7.27 (m, 1H), 4.15--3.99 (m, 4H), 1.23 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.9 (d, *J* = 16.0 Hz), 140.0, 137.9, 131.9, 128.4 (d, *J* = 18.0 Hz), 128.0 (d, *J* = 14.0 Hz), 127.3, 124.9, 123.2 (d, *J* = 89.0 Hz), 121.3, 118.3, 63.0 (d, *J* = 5.0 Hz), 16.2 (d, *J* = 6.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.57; Anal. Calcd for C~17~H~18~BrN~2~O~3~P: C, 49.90; H, 4.43; N, 6.85%. Found: C, 50.07; H, 4.49; N, 6.91%.

Diethyl(2-(naphthalen-1-yl)-2*H*-indazol-3-yl)phosphonate (**3ka**) {#sec4.16}
-------------------------------------------------------------------

Brown gummy mass (73%, 55.48 mg); *R*~f~ = 0.50 (PE/EA = 75:25); ^1^H NMR (400 MHz, CDCl~3~): δ 8.21--8.19 (m, 1H), 8.04 (d, *J* = 8.0 Hz, 1H), 7.95--7.88 (m, 2H), 7.67--7.65 (m, 1H), 7.59 (t, *J* = 8.0 Hz, 1H), 7.54--7.50 (m, 1H), 7.47--7.39 (m, 2H), 7.36--7.33 (m, 1H), 7.06 (d, *J* = 8.0 Hz, 1H), 3.95--3.68 (m, 4H), 1.34--1.07 (m, 3H), 0.79--0.76 (m, 3H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.8 (d, *J* = 16.0 Hz), 137.1, 133.8, 132.3, 130.5 (d, *J* = 9.0 Hz), 127.9 (d, *J* = 19.0 Hz), 127.6, 127.2, 126.8, 126.4, 125.5, 125.1, 124.8, 124.5, 122.8, 121.5, 118.4, 77.3, 76.9, 62.7 (d, *J* = 5.0 Hz), 16.1 (d, *J* = 7.0 Hz), 15.6 (d, *J* = 3.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.11; Anal. Calcd for C~21~H~21~N~2~O~3~P: C, 66.31; H, 5.56; N, 7.36%. Found: C, 66.18; H, 5.53; N, 7.25%.

Diethyl(5-fluoro-2-(*p*-tolyl)-2*H*-indazol-3-yl)phosphonate (**3la**) {#sec4.17}
----------------------------------------------------------------------

Yellow liquid (85%, 61.54 mg); *R*~f~ = 0.45 (PE/EA = 85:15); ^1^H NMR (400 MHz, CDCl~3~): δ 7.83--7.79 (m, 1H), 7.69 (dd, *J* = 2.4 Hz, 9.6 Hz, 1H), 7.54--7.52 (m, 2H), 7.31 (d, *J* = 8.0 Hz, 2H), 7.20--7.15 (m, 1H), 4.13--3.93 (m, 4H), 2.44 (m, 3H), 1.20 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 160.0 (d, *J* = 242.0 Hz), 146.0 (d, *J* = 16.0 Hz), 139.9, 138.5, 129.4, 128.5 (d, *J* = 12.0 Hz), 128.3 (d, *J* = 12.0 Hz), 126.0, 120.5 (d, *J* = 10.0 Hz), 118.6 (d, *J* = 29.0 Hz), 104.3 (d, *J* = 26.0 Hz), 62.9 (d, *J* = 5.0 Hz), 21.3, 16.1 (d, *J* = 7.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.58; Anal. Calcd for C~18~H~20~FN~2~O~3~P: C, 59.67; H, 5.56; N, 7.73%. Found: C, 59.52; H, 5.52; N, 7.83%.

Diethyl(5-fluoro-2-phenyl-2*H*-indazol-3-yl)phosphonate (**3ma**) {#sec4.18}
-----------------------------------------------------------------

Yellow liquid (81%, 56.37 mg); *R*~f~ = 0.45 (PE/EA = 70:30); ^1^H NMR (400 MHz, CDCl~3~): δ 7.84--7.80 (m, 1H), 7.71 (dd, *J* = 9.6 Hz, 2.4 Hz, 1H), 7.68--7.65 (m, 2H), 7.54--7.51 (m, 3H), 7.22--7.17 (m, 1H), 4.13--3.93 (m, 4H), 1.19 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 160.0 (d, *J* = 243.0 Hz), 146.1 (d, *J* = 16.0 Hz), 140.8, 129.7, 128.8, 126.3, 120.5 (d, *J* = 10.0 Hz), 118.9, 118.6, 104.5, 104.2, 62.9 (d, *J* = 5.0 Hz), 16.1 (d, *J* = 6.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.43; Anal. Calcd for C~17~H~18~FN~2~O~3~P: C, 58.62; H, 5.21; N, 8.04%. Found: C, 58.81; H, 5.27; N, 7.96%.

Diethyl(5-chloro-2-phenyl-2*H*-indazol-3-yl)phosphonate (**3na**) {#sec4.19}
-----------------------------------------------------------------

Yellow liquid (82%, 59.69 mg); *R*~f~ = 0.50 (PE/EA = 75:25); ^1^H NMR (400 MHz, CDCl~3~): δ 8.13 (d, *J* = 2.0 Hz, 1H), 7.79--7.77 (m, 1H), 7.67--7.65 (m, 2H), 7.54--7.51 (m, 3H), 7.33 (dd, *J* = 9.2 Hz, 2.0 Hz, 1H), 4.12--3.96 (m, 4H), 1.19 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 147.1 (d, *J* = 15.0 Hz), 140.8, 130.7, 129.8, 128.9 (d, *J* = 16.0 Hz), 128.6, 126.3, 124.9, 122.7, 120.3, 119.8, 77.3, 63.0 (d, *J* = 5.0 Hz), 16.1 (d, *J* = 6.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 4.04; Anal. Calcd for C~17~H~18~ClN~2~O~3~P: C, 55.98; H, 4.97; N, 7.68%. Found: C, 56.16; H, 5.02; N, 7.79%.

Diethyl(5-methoxy-2-(4-methoxyphenyl)-2*H*-indazol-3-yl)phosphonate (**3oa**) {#sec4.20}
-----------------------------------------------------------------------------

Light yellow liquid (83%, 64.74 mg); *R*~f~ = 0.45 (PE/EA = 65:35); ^1^H NMR (400 MHz, CDCl~3~): δ 7.71 (dd, *J* = 9.6 Hz, 2.4 Hz 1H), 7.57--7.53 (m, 2H), 7.34 (d, *J* = 2.4 Hz, 1H), 7.07 (dd, *J* = 9.2 Hz, 2.4 Hz, 1H), 7.01--6.97 (m, 2H), 4.13--4.02 (m, 4H), 4.00--3.96 (m, 3H), 3.95--3.87 (m, 3H), 1.20 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 160.2, 157.2, 145.4 (d, *J* = 16.0 Hz), 134.2, 129.5 (d, *J* = 19.0 Hz), 127.5, 122.7 (d, *J* = 15.0 Hz), 121.0, 119.5, 113.8, 97.4, 77.3, 62.6 (d, *J* = 6.0 Hz), 55.6 (d, *J* = 10.0 Hz), 16.2 (d, *J* = 16.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 5.62; Anal. Calcd for C~19~H~23~N~2~O~5~P: C, 58.46; H, 5.94; N, 7.18%. Found: C, 58.26; H, 6.01; N, 7.27%.

Diethyl(5-methoxy-2-(*p*-tolyl)-2*H*-indazol-3-yl)phosphonate (**3pa**) {#sec4.21}
-----------------------------------------------------------------------

Brown gummy mass (86%, 64.32 mg); *R*~f~ = 0.45 (PE/EA = 65:35); ^1^H NMR (400 MHz, CDCl~3~): δ 7.71 (dd, *J* = 9.2 Hz, 2.4 Hz, 1H), 7.53--7.50 (m, 2H), 7.35 (d, *J* = 2.4 Hz, 1H), 7.29 (d, *J* = 8.0 Hz, 2H), 7.06 (dd, *J* = 9.2 Hz, 2.4 Hz, 1H), 4.12--3.93 (m, 4H), 3.89 (s, 3H), 2.43 (s, 3H), 1.18 (t, *J* = 7.2 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 157.1, 145.4 (d, *J* = 16.0 Hz), 139.4, 138.6, 129.6 (d, *J* = 18.0 Hz), 129.2, 126.0, 123.1, 122.1, 120.9, 119.5, 97.4, 62.6 (d, *J* = 6.0 Hz), 55.5, 21.3, 16.1 (d, *J* = 7.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 5.54; HRMS (ESI-TOF) *m*/*z*: \[M + Na\]^+^ calcd for C~19~H~23~N~2~O~4~PNa, 397.12876; found, 397.1287.

Dimethyl(2-phenyl-2*H*-indazol-3-yl)phosphonate (**3ab**) {#sec4.22}
---------------------------------------------------------

Yellow liquid (81%, 48.92 mg); *R*~f~ = 0.50 (PE/EA = 70:30); ^1^H NMR (400 MHz, CDCl~3~): δ 8.07--8.05 (m, 1H), 7.88--7.85 (m, 1H), 7.68--7.65 (m, 2H), 7.55--7.51 (m, 3H), 7.43--7.39 (m, 1H), 7.32--7.29 (m, 1H), 3.69 (s, 3H), 3.66 (s, 3H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.8 (d, *J* = 16.0 Hz), 140.8, 129.8, 128.9, 128.5 (d, *J* = 5.0 Hz), 128.4, 127.1, 126.3, 125.0, 121.1, 118.4, 53.2 (d, *J* = 5.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 7.74; Anal. Calcd for C~15~H~15~N~2~O~3~P: C, 59.60; H, 5.00; N, 9.27%. Found: C, 59.38; H, 5.03; N, 9.32%.

Dimethyl(2-(*p*-tolyl)-2*H*-indazol-3-yl)phosphonate (**3bb**) {#sec4.23}
--------------------------------------------------------------

Off white solid (84%, 53.08 mg); *R*~f~ = 0.45 (PE/EA = 80:20); mp 82--83 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.06--8.04 (m, 1H), 7.87--7.84 (m, 1H), 7.55--7.51 (m, 2H), 7.42--7.38 (m, 1H), 7.33--7.27 (m, 3H), 3.69 (s, 3H), 3.66 (s, 3H), 2.45 (m, 3H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.6 (d, *J* = 16.0 Hz), 139.7, 138.3, 129.3, 128.3 (d, *J* = 17.0 Hz), 126.9, 125.9, 124.8, 123.5, 121.2 (d, *J* = 32.0 Hz), 118.3, 53.0 (d, *J* = 6.0 Hz), 21.3; ^31^P NMR (162 MHz CDCl~3~): δ 7.93; Anal. Calcd for C~16~H~17~N~2~O~3~P: C, 60.76; H, 5.42; N, 8.86%. Found: C, 60.62; H, 5.37; N, 8.77%.

Diisopropyl(2-(*p*-tolyl)-2*H*-indazol-3-yl)phosphonate (**3bc**) {#sec4.24}
-----------------------------------------------------------------

Yellow gummy mass (85%, 63.24 mg); *R*~f~ = 0.50 (PE/EA = 75:25); ^1^H NMR (400 MHz, CDCl~3~): δ 8.19 (d, *J* = 8.4 Hz, 1H), 7.84--7.81 (m, 1H), 7.58--7.54 (m, 2H), 7.39--7.35 (m, 1H), 7.30--7.24 (m, 3H), 4.74--4.62 (m, 2H), 2.44 (s, 3H), 1.25 (d, *J* = 6.0 Hz, 6H), 1.14 (d, *J* = 6.0 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 148.6 (d, *J* = 16.0 Hz), 139.5, 138.8, 129.2, 128.3 (d, *J* = 20.0 Hz), 126.9, 126.4, 124.3, 124.0, 121.9, 118.1, 72.1 (d, *J* = 6.0 Hz), 24.0 (d, *J* = 4.0 Hz), 23.8 (d, *J* = 4.0 Hz), 21.3; ^31^P NMR (162 MHz CDCl~3~): δ 2.30; Anal. Calcd for C~20~H~25~N~2~O~3~P: C, 64.51; H, 6.77; N, 7.52%. Found: C, 64.72; H, 6.73; N, 7.43%.

Diisopropyl(5-fluoro-2-phenyl-2*H*-indazol-3-yl)phosphonate (**3mc**) {#sec4.25}
---------------------------------------------------------------------

Yellow liquid (80%, 60.16 mg); *R*~f~ = 0.55 (PE/EA = 80:20); ^1^H NMR (400 MHz, CDCl~3~): δ 7.82--7.79 (m, 2H), 7.69--7.66 (m, 2H), 7.51--7.50 (m, 3H), 7.21--7.16 (m, 1H), 4.71--4.63 (m, 2H), 1.23 (d, *J* = 6.4 Hz, 6H), 1.13 (d, *J* = 6.4 Hz, 6H); ^13^C{^1^H} NMR (100 MHz, CDCl~3~): δ 159.8 (d, *J* = 242.0 Hz), 146.1 (d, *J* = 16.0 Hz), 141.1, 129.5, 128.7, 126.4, 120.3 (d, *J* = 10.0 Hz), 119.6, 118.9, 118.6, 104.7 (d, *J* = 26.0 Hz), 72.2 (d, *J* = 6.0 Hz), 23.9 (d, *J* = 5.0 Hz), 23.8 (d, *J* = 4.0 Hz); ^31^P NMR (162 MHz CDCl~3~): δ 1.87; Anal. Calcd for C~19~H~22~FN~2~O~3~P: C, 60.63; H, 5.89; N, 7.44%. Found: C, 60.47; H, 5.96; N, 7.50%.
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